Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$56.17 USD
+1.02 (1.85%)
Updated Jul 25, 2024 09:48 AM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Halozyme Therapeutics (HALO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.80 | $71.00 | $49.00 | 4.81% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Halozyme Therapeutics comes to $57.80. The forecasts range from a low of $49.00 to a high of $71.00. The average price target represents an increase of 4.81% from the last closing price of $55.15.
Analyst Price Targets (10)
Broker Rating
Halozyme Therapeutics currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HALO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/7/2024 | Piper Sandler | Joseph M Catanzaro | Hold | Hold |
5/8/2024 | Goldman Sachs | Corinne Johnson | Hold | Hold |
5/8/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
4/25/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
4/17/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/16/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Brendan Smith | Strong Buy | Strong Buy |
2/21/2024 | SVB Securities | David Risinger | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $57.80 |
LT Growth Rate | 27.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | 0.78 |